TP53 and chronic myelomonocytic leukemia: Even though numbers of patients with available NGS in the three series are small, it is of some interest the observation that TP53 mutation- – which is generally reported in <5% of CMML patients-, is in the 13%-14% range in CMML-RS/SF3B1 (possibly due to some cases of CMML-RS with unknown SF3B1 status) (Figures 1A, B).